Skip to Content

Find Comparable ETFs for iShares Biotechnology ETF

iShares Biotechnology ETF

IBB - NGM
ETF Category
Health & Biotech Equities
Asset Class
Equity
AUM
$7,909M
Expense Ratio
0.45% (Moderate)
Trading Volume
572.9K (Moderate)
Issuer
BlackRock, Inc.
Number of Holdings
211
Inception Date
2001-02-05 (24 years)
Momentum
Very Weak Weak Very Strong
AUM
Micro Medium Very Large
Concentration
Very Low Very Low Very High
Volatility
Very Low Moderate Very High
Overview
Momentum
Concentration
ESG
P/E Ratio
15.68
Annual Dividend Rate
0.28%
Beta
0.84
50-Day Moving Average
$135.89
Price vs. 50-Day MA
-0.01%
200-Day Moving Average
$140.48
Price vs. 200-Day MA
-3.27%
1 Year Fund Flow
-$566M (-7% of AUM)
3 Year Fund Flow
-$1,391M (-18% of AUM)
5 Year Fund Flow
-$1,540M (-19% of AUM)
% in Top 10 Holdings (Market Cap Weighted)
51.41%
% in Top 15 Holdings (Market Cap Weighted)
59.72%
% in Top 50 Holdings (Market Cap Weighted)
84.54%
ESG Score
6.7800
ESG Peer %
68.42
ESG Global %
60.65
Carbon Intensity (Tons CO2e/$M Sales)
22
ESG Exclusion %
0.00
Sustainable Impact %
33.73

First Trust NYSE Arca Biotechnology Index Fund

FBT - PCX
View FBT's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $1,178M
Expense Ratio: 0.56% (Moderate)
Volume: 28.0K (Low)
Issuer: First Trust
Holdings: 31
Inception: 2006-06-19 (18 years)
Neutral Momentum
Medium AUM
High Concentration
Low Volatility
Compare
Overview
Momentum
Concent.
ESG

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 93%

R-squared: 86%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 7
  • FBT in IBB's comparables: Yes
  • IBB in FBT's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

valuation
A+

valuation

Compares valuation metrics to assess if the assets are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 17.55 vs 15.68

A high score indicates that the market values these assets similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • FBT Beta: 0.79 (Low)
  • IBB Beta: 0.84 (Low)
  • FBT 200-day Volatility: 14.96%
  • IBB 200-day Volatility: 15.85%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • FBT Price vs 200-day MA: 104%
  • IBB Price vs 200-day MA: 97%

Performance Comparison:

Period FBT IBB
Year_1 9% 14%
Year_3 0% -4%
Year_5 4% 7%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: PCX vs NGM

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • FBT Dividend Yield: 0%
  • IBB Dividend Yield: 0%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
17.55
Annual Dividend Rate
0.00%
Beta
0.79
50-Day Moving Average
$174.15
Price vs. 50-Day MA
-0.39%
200-Day Moving Average
$167.51
Price vs. 200-Day MA
3.56%
1 Year Fund Flow
-$306M (-26% of AUM)
3 Year Fund Flow
-$646M (-55% of AUM)
5 Year Fund Flow
-$1,855M (-158% of AUM)
% in Top 10 Holdings
37%
% in Top 15 Holdings
53%
% in Top 50 Holdings
100%
ESG Score
6.1300
ESG Peer %
37.59
ESG Global %
40.26
Carbon Intensity
28
ESG Exclusion %
0.00
Sustainable Impact %
40.27

Invesco Pharmaceuticals ETF

PJP - PCX
View PJP's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $285M
Expense Ratio: 0.56% (Moderate)
Volume: 8.7K (Very Low)
Issuer: Invesco
Holdings: 23
Inception: 2005-06-23 (19 years)
Neutral Momentum
Small AUM
Moderate Concentration
Low Volatility
Compare
Overview
Momentum
Concent.
ESG

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 82%

R-squared: 68%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 2
  • IBB in PJP's comparables: Yes
  • PJP in IBB's comparables: No

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

valuation
A+

valuation

Compares valuation metrics to assess if the assets are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 15.68 vs 17.24

A high score indicates that the market values these assets similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • IBB Beta: 0.84 (Low)
  • PJP Beta: 0.66 (Low)
  • IBB 200-day Volatility: 15.85%
  • PJP 200-day Volatility: 11.88%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • IBB Price vs 200-day MA: 97%
  • PJP Price vs 200-day MA: 102%

Performance Comparison:

Period IBB PJP
Year_1 14% 10%
Year_3 -4% 3%
Year_5 7% 9%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: NGM vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • IBB Dividend Yield: 0%
  • PJP Dividend Yield: 1%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
17.24
Annual Dividend Rate
0.89%
Beta
0.66
50-Day Moving Average
$84.95
Price vs. 50-Day MA
1.86%
200-Day Moving Average
$85.05
Price vs. 200-Day MA
1.74%
1 Year Fund Flow
-$35M (-12% of AUM)
3 Year Fund Flow
-$168M (-59% of AUM)
5 Year Fund Flow
-$234M (-82% of AUM)
% in Top 10 Holdings
56%
% in Top 15 Holdings
77%
% in Top 50 Holdings
100%
ESG Score
5.7000
ESG Peer %
27.26
ESG Global %
32.37
Carbon Intensity
32
ESG Exclusion %
0.00
Sustainable Impact %
27.29

ALPS Medical Breakthroughs ETF

SBIO - PCX
View SBIO's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $116M
Expense Ratio: 0.50% (Moderate)
Volume: 11.6K (Low)
Issuer: SS&C
Holdings: 102
Inception: 2014-12-30 (10 years)
Weak Momentum
Small AUM
Very High Concentration
High Volatility
Compare
Overview
Momentum
Concent.
ESG

The iShares Nasdaq Biotechnology ETF includes large and small-cap biotech stocks, aligning with SBIO's focus on medical advancements.

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 83%

R-squared: 69%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • IBB in SBIO's comparables: Yes
  • SBIO in IBB's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • IBB Beta: 0.84 (Low)
  • SBIO Beta: 0.92 (Average)
  • IBB 200-day Volatility: 15.85%
  • SBIO 200-day Volatility: 27.48%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • IBB Price vs 200-day MA: 97%
  • SBIO Price vs 200-day MA: 86%

Performance Comparison:

Period IBB SBIO
Year_1 14% 14%
Year_3 -4% -7%
Year_5 7% 0%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: NGM vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • IBB Dividend Yield: 0%
  • SBIO Dividend Yield: -1%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
N/A
Annual Dividend Rate
0.19%
Beta
0.92
50-Day Moving Average
$32.36
Price vs. 50-Day MA
-5.04%
200-Day Moving Average
$35.54
Price vs. 200-Day MA
-13.53%
1 Year Fund Flow
-$9M (-8% of AUM)
3 Year Fund Flow
-$53M (-46% of AUM)
5 Year Fund Flow
-$58M (-50% of AUM)
% in Top 10 Holdings
27%
% in Top 15 Holdings
38%
% in Top 50 Holdings
80%
ESG Score
5.3000
ESG Peer %
21.43
ESG Global %
27.18
Carbon Intensity
52
ESG Exclusion %
0.00
Sustainable Impact %
8.43
Toggle between similar ETFs and stocks for comparison.

Loading comparable ETFs ...

First Trust NYSE Arca Biotechnology Index Fund

FBT - PCX
A+
$173.47 -0.91 (-0.52%)
Health & Biotech Equities
Equity
AUM: $1,178M
Expense Ratio: 0.56% (Moderate)
Volume: 28.0K (Low)
Issuer: First Trust
Holdings: 31
Inception: 2006-06-19 (18 years)
Neutral Momentum
Medium AUM
High Concentration
Low Volatility

Invesco Pharmaceuticals ETF

PJP - PCX
A+
$86.53 +0.54 (0.63%)
Health & Biotech Equities
Equity
AUM: $285M
Expense Ratio: 0.56% (Moderate)
Volume: 8.7K (Very Low)
Issuer: Invesco
Holdings: 23
Inception: 2005-06-23 (19 years)
Neutral Momentum
Small AUM
Moderate Concentration
Low Volatility

ALPS Medical Breakthroughs ETF

SBIO - PCX
A+
$30.73 -0.10 (-0.32%)
Health & Biotech Equities
Equity
AUM: $116M
Expense Ratio: 0.50% (Moderate)
Volume: 11.6K (Low)
Issuer: SS&C
Holdings: 102
Inception: 2014-12-30 (10 years)
Weak Momentum
Small AUM
Very High Concentration
High Volatility